Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA)

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 3, 2011, Pages 705-715

  Basu, Hirak S ^a   Mahlum, Amy ^a   Mehraein Ghomi, Farideh ^a   Kegel, Stacy J ^a   Guo, Song ^a   Peters, Noel R ^a   Wilding, George ^a  

^a University of Wisconsin Health   (United States)

Author keywords

Drug metabolism; Histone deacetylase; Oxidative stress; Prostate cancer

Indexed keywords

ACETYLCYSTEINE; ACYLTRANSFERASE; ALPHA TOCOPHEROL; ANTIOXIDANT; HISTONE DEACETYLASE; METRIBOLONE; REACTIVE OXYGEN METABOLITE; SPERMINE ACETYLTRANSFERASE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELLULAR STRESS RESPONSE; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; BREAST TUMOR; COLON TUMOR; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANTIOXIDANTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MALE; MASS SPECTROMETRY; OXIDATIVE STRESS; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; VITAMIN E;

EID: 79953788698     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1364-3     Document Type: Article

References (22)

1. MA Glozak E Seto 2007 Histone deacetylases and cancer Oncogene 26 5420 5432 1:CAS:528:DC%2BD2sXovFeku7Y%3D 10.1038/sj.onc.1210610 17694083 (Pubitemid 47255924)
2. JM Mehnert WK Kelly 2007 Histone deacetylase inhibitors: biology and mechanism of action Cancer J 13 23 29 1:CAS:528:DC%2BD2sXlsVWhtbY%3D 10.1097/PPO.0b013e31803c72ba 17464243
3. AJ Frew RW Johnstone JE Bolden 2009 Enhancing the apoptotic and therapeutic effects of HDAC inhibitors Cancer Lett 280 125 133 1:CAS:528:DC%2BD1MXmsF2jtrY%3D 10.1016/j.canlet.2009.02.042 19359091
4. VM Richon X Zhou RA Rifkind PA Marks 2001 Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers Blood Cells Mol Dis 27 260 264 1:STN:280:DC%2BD3M3ms1Wmtw%3D%3D 10.1006/bcmd.2000.0376 11358386 (Pubitemid 32299781)
5. SK Seo HO Jin HC Lee, et al. 2008 Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells Mol Pharm 73 1005 1012 1:CAS:528:DC%2BD1cXjt1egsbk%3D
6. M Duvic R Talpur X Ni, et al. 2007 Phase 2 trial of oral SAHA (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 31 39 1:CAS:528:DC%2BD2sXivVyrt7g%3D 10.1182/blood-2006-06- 025999 16960145 (Pubitemid 46053039)
7. JS Horoszewicz SS Leong E Kawinski, et al. 1983 LNCaP model of human prostatic carcinoma Cancer Res 43 1809 1818 1:CAS:528:DyaL3sXhsFylsLg%3D 6831420 (Pubitemid 13122588)
8. JS Horoszewicz SS Leong TM Chu, et al. 1980 The LNCaP cell line-a new model for studies on human prostatic carcinoma Models for CaP 37 115 132 1:STN:280:DyaL3c3ht1alsg%3D%3D
9. MO Ripple WF Henry RP Rago G Wilding 1997 Pro-oxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells J Nat Cancer Inst 89 40 48 1:CAS:528:DyaK2sXjvVamsg%3D%3D 10.1093/jnci/89.1.40 8978405 (Pubitemid 26428076)
10. TH Luu RJ Morgan L Leong, et al. 2008 A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study Clin Cancer Res 14 7138 7142 1:CAS:528: DC%2BD1cXhtlensL7I 10.1158/1078-0432.CCR-08-0122 18981013
11. J Vansteenkiste E Van Cutsem H Dumez, et al. 2008 Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal or non-small cell lung cancer Invest New Drugs 26 483 488 1:CAS:528:DC%2BD1cXhtVSku7fM 10.1007/s10637-008-9131-6 18425418
12. RR Rosato S Grant 2005 Histone deacetylase inhibitors: insights into mechanisms of lethality Exp Opin Ther Targ 9 809 824 1:CAS:528: DC%2BD2MXmvFels7s%3D 10.1517/14728222.9.4.809 (Pubitemid 41131680)
13. I Rahman IM Adcock 2006 Oxidative stress and redox regulation of lung inflammation in COPD Eur Respir J 28 219 242 1:CAS:528:DC%2BD28XnslGqtrk%3D 10.1183/09031936.06.00053805 16816350 (Pubitemid 44914279)
14. Y Samuni W Flores-Santana MC Krishna JB Mitchell DA Wink 2009 The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation Free Radic Biol Med 47 419 423 1:CAS:528:DC%2BD1MXotl2ltr8%3D 10.1016/j.freeradbiomed.2009.05.011 19447172
15. RA Parise JL Holleran JH Beumer S Ramalingam MJ Egorin 2006 A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum J Chromatogr B Analyt Technol Biomed Life Sci 840 108 115 1:CAS:528:DC%2BD28XotFyks74%3D 10.1016/j.jchromb.2006.04.044 16725386 (Pubitemid 44163473)
16. HS Basu TA Thompson DR Church, et al. 2009 A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model Cancer Res 69 7689 7695 1:CAS:528:DC%2BD1MXht1Skt7jP 10.1158/0008-5472.CAN-08- 2472 19773450
17. L Xiao P Celano AR Mank, et al. 1992 Structure of the human spermidine/spermine N1-acetyltransferase gene (exon/intron gene organization and localization to Xp22.1) Biochem Biophys Res Commun 187 1493 1502 1:CAS:528:DyaK38XmsVKnsbo%3D 10.1016/0006-291X(92)90471-V 1417826
18. CE Thomas NL Kellher CA Mizzen 2006 Mass spectrometric characterization of human histone H3: a bird's eye view J Proteome Res 5 240 247 1:CAS:528:DC%2BD28XisFCnsg%3D%3D 10.1021/pr050266a 16457588 (Pubitemid 43222291)
19. C Borek 2004 Dietary antioxidants and human cancer Integr Cancer Ther 3 333 341 1:CAS:528:DC%2BD2cXhtFSjur%2FO 10.1177/1534735404270578 15523104 (Pubitemid 39552427)
20. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzym Regul 22 27 55 1:CAS:528:DyaL2cXktlaksLk%3D 10.1016/0065-2571(84)90007-4
21. JS Ungerstedt Y Sowa WS Xu, et al. 2005 Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors Proc Natl Acad Sci (USA) 102 673 678 1:CAS:528:DC%2BD2MXis1Cqs78%3D 10.1073/pnas.0408732102 (Pubitemid 40282724)
22. WK Kelly OA O'Connor LM Krug, et al. 2005 Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 3923 3931 1:CAS:528:DC%2BD2MXmtVahtLw%3D 10.1200/JCO.2005.14.167 15897550 (Pubitemid 46218695)